Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, and Patient Eligibility

By João L. Carapinha

April 8, 2025

The German Federal Joint Committee (G-BA) has approved a new indication for Pembrolizumab Enfortumab therapy in combination with Enfortumab Vedotin as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. This decision is based on a structured benefit assessment comparing this therapy to standard treatments. It focuses on patients’ eligibility for cisplatin-based regimens. For those ineligible for either cisplatin or carboplatin, no additional benefit was found.

Clinical Effectiveness Overview

  • Mortality Benefits: In cisplatin-eligible patients, the combination therapy showed a mortality benefit but lacked quantifiable superiority over cisplatin/gemcitabine. For carboplatin-eligible patients, it demonstrated significant mortality improvement compared to carboplatin/gemcitabine, along with symptomatic benefits like reduced nausea and constipation. However, for patients ineligible for both, no efficacy was shown over alternatives like Atezolizumab monotherapy or best supportive care.

Economic Aspects

  • Cost Implications: The annual treatment costs for Pembrolizumab Enfortumab therapy are much higher than standard therapies, estimated at €181,464 per patient. Standard options include carboplatin, and gemcitabine, or maintenance therapy with avelumab, depending on the regimen and patient subgroup.

Safety Profile and Adverse Events

  • Benefits and Risks: The combination therapy has advantages, such as fewer severe adverse effects, and risks, including immune-related side effects like severe hyperglycemia.

Regulatory and Assessment Framework

The G-BA conducts early benefit assessments under the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG). This process compares new therapies against existing standards to ensure efficient resource use in Germany’s statutory health insurance (GKV) system. Pembrolizumab is a PD-1 checkpoint inhibitor, while Enfortumab Vedotin is an antibody-drug conjugate targeting Nectin-4.

Implications for Healthcare Economics and Access

  1. Healthcare Economics: The high cost of Pembrolizumab Enfortumab therapy raises affordability concerns. Its benefits for some subpopulations may limit widespread use.
  2. Reimbursement Challenges: High costs and limited evidence for certain groups may hinder reimbursement. Price negotiations with GKV payers could lead to reductions.
  3. Addressing Unmet Needs: The lack of benefits for cisplatin- and carboplatin-ineligible patients highlights the need for alternative treatments. More research could improve outcomes.

Final Reflections

The G-BA’s decision reflects a tailored approach to clinical effectiveness. While Pembrolizumab Enfortumab therapy shows promise for select groups, its high costs and selective effectiveness emphasize the need for precision medicine and cost containment. For details, see the G-BA’s official assessment.

Reference url

Recent Posts

NHI Bill court ruling
      

South Africa NHI Bill Court Ruling Calls for Scrutiny

🔍 What does a recent court ruling mean for South Africa’s healthcare system?

This pivotal decision from the Gauteng High Court mandates President Cyril Ramaphosa to justify his signing of the National Health Insurance Bill, opening the door for judicial review of executive decisions in healthcare legislation. As the implications of this ruling unfold, it reflects a significant check on executive power, particularly in contentious policy areas.

Curious to learn more about the potential impact on the NHI Act and South Africa’s healthcare future? Dive into the full article for comprehensive insights!

#SyenzaNews #HealthcarePolicy #HealthTech #Governance

health technology assessment Oman
            

Implementing Health Technology Assessment in Oman

🚀 Is Oman ready to revolutionize its healthcare decision-making?

A new roadmap for health technology assessment (HTA) is set to enhance evidence-based practices, streamline resource allocation, and address the challenges of rising healthcare costs. This phased strategy not only focuses on immediate capacity-building but also envisions comprehensive integration over the next decade!

Dive into the article to explore Oman’s strategic approach to improving healthcare delivery and its implications for the region.

#SyenzaNews #HealthTechnology #HealthcarePolicy #Innovation

TAVR asymptomatic approval
         

TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis

🚨 Is it time to rethink how we treat asymptomatic severe aortic stenosis?

The FDA’s recent approval of the Edwards Lifesciences Sapien 3 TAVR devices could revolutionize cardiac care, allowing earlier intervention that dramatically reduces severe outcomes. This new approach, supported by the groundbreaking EARLY TAVR trial, challenges traditional “watchful waiting” strategies and emphasizes the need for proactive treatment to enhance patient outcomes and potentially lower healthcare costs.

Curious to learn more about this pivotal shift in medical practice? Dive into the full article for in-depth insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.